Drug Discovery 2010 Organization: European Laboratory Robotics Interest Group Location: Richo Arena, Coventry, UK Date: 1-2 September 2010 Poster:In Vitro Models of Mechanisms of Human Toxicity: Validation and Application for Early Drug Discovery and Screening Presenters: Robert Annand, Ph.D.; Mary Jacewicz, Ph.D.; Katya Tsaioun, Ph.D., Apredica
Cell-Based Assays Organization: Vision Gain Location: BSG Conference Centre, London, UK Date: 20-22 September 2010 Topic: Cell-based assays and high-content imaging for early identification of liver toxicity liability. What can be predicted early in discovery and why bother? Presenter: Katya Tsaioun, Ph.D., Apredica
SOT Annual Meeting & ToxExpo Organization: Society of Toxicology Location: Walter Washington Convention Center, Washington, DC Date: 6-10 March 2011 Program: Exhibition Hall Presenter: Katya Tsaioun, Ph.D., Apredica
Past Events
Predictive ADME and Toxicology Organization: eCheminfo Location: Medical Sciences Teaching Centre, Oxford University, Oxford, UK Date: 2-6 August 2010 Topic:In Vitro Assays that Predict Mechanisms of Human Organ Toxicity Speaker: Katya Tsaioun, Ph.D., Apredica
ADMET Organization: SMi Group Location: Crowne Plaza Hotel - St James, London, United Kingdom Date: 7-8 July 2010 Topic: Mechanisms of Human (Hepato)Toxicity Speaker: Katya Tsaioun, Ph.D., Apredica
The Science Behind Personalized Medicine Organization: MassBio Location: MassBio offices, One Cambridge Center, Cambridge, MA Date: 17 June 2010 Topic: Allelic Variation in Drug Metabolism Speakers: Katya Tsaioun, Ph.D.; Robert Annand, Ph.D., Apredica
Applied Pharmaceutical Technology 2010 Organization: The Boston Society Location: Merck’s Boston Auditorium, Boston, MA Date: 17-19 May 2010 Topic: Assays that Detect Mechanisms of DILI in Discovery Stage: When De-Risking Makes Most Sense Speaker: Katya Tsaioun, Ph.D., Apredica
High Throughput Screening Organization: SMi Group Location: Crowne Plaza Hotel - St James, London, United Kingdom Date: 26-27 April 2010 Topic: HCS and Multi-Parameter Readouts: De-Risking Drug Discovery Programs Speaker: Katya Tsaioun, Ph.D., Apredica
SOT Annual Meeting & ToxExpo Organization: Society of Toxicology Location: Exhibit Hall E, Salt Palace Convention Center, Salt Lake City, UT Date: 7-11 March 2010 Poster: A Sensitive HCS Assay to Evaluate Linezolid Toxicity, Using Sub-Lethal Cytotoxic Measurements in HepG2 Cells Presenter: Katya Tsaioun, Ph.D., Apredica
SOT Annual Meeting & ToxExpo - Exhibitor-Hosted Sessions Organization: Society of Toxicology Location: Room 155 B, Exhibit Hall E, Salt Palace Convention Center, Salt Lake City, UT Date: 10 March 2010, 12:15 PM – 1:15 PM Topic: Mechanisms of Toxicity and Prediction of Whole-Organ Toxicity: In Vitro Assays and Their Validation. What Can We Predict Early On to Avoid Costly Mistakes Later? Presenter: Katya Tsaioun, Ph.D., Apredica
Screening Europe Organization: Select Biosciences Location: Barcelona, Spain Date: 11-12 February 2010 Topic: HCS for Prediction of Mechanisms of Drug Toxicities: Prediction of Organ Toxicity or Specific Mechanisms? Speaker: Katya Tsaioun, Ph.D., Apredica
Growing the Great Idea Organization: 128 Venture North Location: Enterprise Center, Salem, MA Date: 22 January 2010 Speaker: Doug Bates, M.S., M.B.A., Chief Business Officer, Apredica
Cell Based Assays Organization: SMi Conferences Location: Crowne Plaza Hotel - St James, London, London, UK Date: 18-19 November 2009 Topic: Cell-Based Assays that Detect Mechanisims of Human Hepatatotoxicity Speaker: Katya Tsaioun, Ph.D., Apredica
How to Solve the Problem of Access to Human Tissues for Medical Research Organization: Safer Medicines Trust Location: House of Lords, Parliament, London, UK Date: 20 October 2009 Topic: De-Risking Drug Discovery with ADDME - Avoiding Drug Development Mistakes Early. Alternatives to Laboratory Animals. Speaker: Katya Tsaioun, Ph.D., Apredica
16th North American Regional ISSX Meeting Organization: International Society for the Study of Xenobiotics Location: Baltimore Marriott Waterfront Hotel, Baltimore, MD Date: 18-22 October 2008 Poster: Simultaneous Determination of Cyp450 Induction and Metabolism in Metabolically Competent Human Hepatocyte Cell Line HepaRG Participants: Robert R. Annand, Ph.D.; Mary Jacewicz, Ph.D.; Katya Tsaioun, Ph.D., Apredica Request poster Poster: Quantity Production of Metabolites Using HepaRG Human Hepatic Cells Participants: Robert R. Annand, Ph.D.; Mary Jacewicz, Ph.D.; Katya Tsaioun, Ph.D., Apredica Request poster
2nd Alzeheimer's Disease Translational Research Investigators' Meeting Organization: National Institute on Aging Location: Bethesda, MD Date: 10-11 September 2009 Topic: ADDME: Avoiding Drug Development Mistakes Early - Academic perspective Speaker: Katya Tsaioun, Ph.D., Apredica
Drug Discovery: Easing the Chemistry Bottleneck Organization: Opal Events Location: Pennsylvania Convention Center, Philadelphia, PA Date: 8-9 June 2009 Topic: Teaming up to Tame the Bottleneck: Industrial-Academic Interactions Speaker: Katya Tsaioun, Ph.D., Apredica
Applied Pharmaceutical Toxicology 2009 Organization: Applied Pharmaceutical Toxicology Location: Harvard Medical Conference Center, Boston, MA Date: 11-13 May 2009 Topic: Cell Models for Prediction of Human Toxicity. Validation and Case Studies Speaker: Katya Tsaioun, Ph.D., Apredica
PCI Synthesis Open House Organization: PCI Synthesis Location: 9 Opportunity Way, Newburyport MA Date: 8 May 2009 9:00-11:00am Topic: ADDME - Avoiding Drug Development Mistakes Early Speaker: Katya Tsaioun, Ph.D., Apredica
First Friday Bioscience Seminar Organization: North Shore Technology Council Location: 100 Cummings Center, Suite 339-F, Beverly, MA 01915 Date: 6 March 2009 12:30 PM - 02:00 PM Topic: Drugs, Toxicity and Triage - new developments in the science of ADME-Tox testing for screening candidate drugs Speaker: Katya Tsaioun, Ph.D., Apredica
ADMET Europe Organization: Select Biosciences Location: Hotel Berlin, Lützowplatz 17 10785, Berlin, Germany Date: 23-25 February 2009 Topic: Reactive Intermediate Screen for Early Identification of Idiosyncratic Drug Reactions Speaker: Katya Tsaioun, Ph.D., Apredica
Predictive Human Toxicity and ADME/Tox Studies Organization: Mondial Research Group Location: Brussels, Belgium Date: 22-23 January 2009 Topic: Reducing the Cost of Drug Development using ADME Studies: Recent FDA Guidelines and Case Studies Speaker: Katya Tsaioun, Ph.D., Apredica
Drug Delivery 2008 Organization: Pharmaceutical Education Associates Location: San Diego, CA Date: 28-30 July 2008 Topic: Absorption and Toxicity in Intranasal and Lung Delivery Speaker: Katya Tsaioun, Ph.D., Apredica
SMi’s 3rd Annual ADMET Conference Organization: SMi Publishing Location: The Hatton, at etc. venues, London, UK Date: 2 & 3 July 2008 Topic: Combining In Vitro and In Silico Methods to Avoid Drug Development Mistakes Early Speaker: Katya Tsaioun, Ph.D., Apredica; Pranas Japartas, Pharma Algorithms
Avoiding Hepatotoxic Surprises – An Update on Predictive Tools Location: 500 Tech Square, Main St, Cambridge, MA Date: 8:30 – 11:30am. 18 April 2008 Topic: ADDMEsm Avoiding Drug Development Mistakes Early -- Approaching Early Toxicity Assessment as a Business Decision Speaker: Katya Tsaioun, Ph.D., Apredica
Breaking New Ground with Marketing Location: Odeum Room, Campus Center, Worcester Polytechnic Institute, Worcester, MA Date: 5:30 - 9:00pm. 8 April 2008 Topic: How to Market to Pharma Companies Speaker: Katya Tsaioun, Ph.D., Apredica
Seminar: Early Cardiac Toxicity Screening Location: Cambridge, MA
British Consulate-General
One Memorial Drive, Suite 1500, Cambridge, MA 02142 Directions & ParkingMap
Date: 7 June 2007, 8:00 am to 10:00 am
Registration and breakfast: 8:00 - 8:30 am
Seminar: 8:30 - 9:30 am
Discussion and networking: 9:30 - 10:00 am
Program: Drug-Drug Interaction and Cardiac Toxicity Speakers: Arthur "Buzz" Brown, ChanTest; Katya Tsaioun, Ph.D., Apredica
Safety assessment prior to human clinical trials has become the norm in drug development.
It is crucial for reducing attrition in phase 2 and later development, where 75% of failures is
now due to safety and metabolism issues. To address this hurdle, the drug discovery and development
process is undergoing a paradigm shift. Discovery and development teams are functionally merging
so that safety issues are investigated much earlier than ever before.
The most common safety issues are associated with CYP450 and ion channels. CYP450 inhibition
can exacerbate interaction with ion channels. A prominent recent example of the consequences of
failure to investigate cardiac risk and CYP-3A4 inhibition is the withdrawal of Terfenadine from the market.
This seminar will feature:
How cardiac safety and other ADME and toxicity issues can be assessed early, quickly, and economically.
Case studies of drugs withdrawn from the market due to cardiac safety.
How to use hERG data.
Literature review on the correlation of human in vivo QT prolongation with available in vitro tests.
Strategies and techniques for early assessment of cardiac risk.
Which therapeutic areas and types of drug-discovery programs should be most concerned about cardiac safety.
Ask the experts your questions about how to address cardiac safety issues in your programs.
Speakers: Arthur Brown, M.D., ChanTest
Dr. Arthur M. "Buzz" Brown is the founder and CEO of ChanTest, a drug safety testing company specializing in ion channels.
He has more than 30 years of experience in ion channel biophysics. His research delineated the pores of voltage-gated
and inwardly rectifying potassium channels. At present, his research is on ion channel trafficking with special
emphasis on the hERG channel. He holds seven patents concerning ion channels and prevention and treatment of cardiac arrhythmias.
He is Adjunct Professor of Physiology and Biophysics, School of Medicine, Case Western Reserve University.
Dr. Brown has organized two academic departments at the University of Texas Medical Branch and Baylor College of
Medicine and one research institute, the Rammelkamp Center for Education and Research, MetroHealth Campus, Case Western Reserve University.
Katya Tsaioun, Ph.D., Apredica
Bio 2007 Location: MBC Office, One Cambridge Center, 9th Floor, Cambridge, MA Date: 6-9 May 2007 Program: Exhibition hall - Emerging Companies Pavilion
"Managing Virtual Teams" -- Massachusetts Biotechnology Council Location: MBC Office, One Cambridge Center, 9th Floor, Cambridge, MA Date: 19 April 2007 Program: Case study of a collaborative relationship between a small drug-discovery company and contract research teams Speaker: Katya Tsaioun, Ph.D., Apredica
Y50K Biotechnology Entrepreneurial Competition Location: New Haven, CT Date: 14 April 2007 Program: Final judging for the Y50K biotechnology business plan competition Judge: Katya Tsaioun, Ph.D., Apredica, biotech judge
From Discovery to IND Location: Baltimore, MD Date: 13-14 March 2007 Topic: A Surer Path to IND: Early ADME-Tox Models for Reducing Downstream Risk of Drug Development Speakers: Katya Tsaioun, Ph.D., Apredica; Ania Knap, Ph.D., MaxThera
Predictive Human Toxicity and ADME/Tox Studies Location: Brussels, Belgium Date: 25-26 January 2007 Topic: Early ADME-Tox Models for Reducing Downstream Risk of Drug Development and Increasing Productivity of Drug Discovery Organizations Speaker: Katya Tsaioun, Ph.D., Apredica
